Alkermes plc Total Liabilities

Latest as of March 2026: €2.51 Billion EUR ≈ $2.93 Billion USD

Alkermes plc total liabilities. Based on the latest financial reports, Alkermes plc (8AK) has total liabilities worth €2.51 Billion EUR (≈ $2.93 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Alkermes plc to measure how many days the company can operate on defensive assets alone.

Total Liabilities of Alkermes plc (2013–2025)

Total liabilities of Alkermes plc from 2013 to 2025. This chart illustrates how Alkermes plc's total liabilities have evolved over time, based on quarterly financial data. Check 8AK financial resilience to evaluate the company's liquid asset resilience ratio.

Alkermes plc Competitors by Total Liabilities

The table below lists competitors of Alkermes plc ranked by their total liabilities.

Company Country Total Liabilities
Sonic Healthcare Ltd
AU:SHL
Australia AU$8.29 Billion
Schaeffler AG
XETRA:SHA0
Germany €18.85 Billion
Lottomatica Group SpA
NYSE:LOTMY
USA $3.13 Billion
Unicaja Banco SA
MC:UNI
Spain €91.34 Billion
Fluor Corporation
NYSE:FLR
USA $4.75 Billion
Huadong Medicine Co Ltd
SHE:000963
China CN¥15.43 Billion
Korea Aerospace Industries
KO:047810
Korea ₩8.23 Trillion
Henan Shijia Photons Technology Co Ltd
SHG:688313
China CN¥1.07 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Alkermes plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Alkermes plc.

Liquidity & Leverage Metrics

Alkermes plc Total Liabilities Ratios Explained

Alkermes plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.27 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.43 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Alkermes plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Alkermes plc (2013–2025)

The table below shows the annual total liabilities of Alkermes plc from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 €667.70 Million
≈ $780.61 Million
+13.06%
2024-12-31 €590.59 Million
≈ $690.46 Million
-36.74%
2023-12-31 €933.54 Million
≈ $1.09 Billion
+1.45%
2022-12-31 €920.23 Million
≈ $1.08 Billion
+0.91%
2021-12-31 €911.90 Million
≈ $1.07 Billion
+39.49%
2018-12-31 €653.72 Million
≈ $764.27 Million
+9.98%
2017-12-31 €594.42 Million
≈ $694.94 Million
+14.99%
2016-12-31 €516.94 Million
≈ $604.36 Million
-4.53%
2015-12-31 €541.47 Million
≈ $633.03 Million
+3.69%
2014-12-31 €522.22 Million
≈ $610.53 Million
+1.92%
2013-12-31 €512.40 Million
≈ $599.05 Million
--

About Alkermes plc

F:8AK Germany Drug Manufacturers - Specialty & Generic
Market Cap
$7.71 Billion
€6.59 Billion EUR
Market Cap Rank
#2882 Global
#580 in Germany
Share Price
€39.31
Change (1 day)
-0.81%
52-Week Range
€23.40 - €48.19
All Time High
€48.19
About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more